Envisagenics Raises Series B To Fuel Ai-enabled Novel Therapeutic Pipeline And Expand Depth And Breadth Of Commercial Offerings By Investing.com

Envisagenics, an AI-driven biotechnology company, has announced a Series B fundraising round with participation from existing and new investors. The funding will be used to further develop the company’s pipeline of novel oncology assets and scale its commercial offerings using its cloud-based AI drug discovery platform, SpliceCore. Envisagenics has established collaborations with Biogen, Johnson & Johnson, and Bristol Myers Squibb, and plans to advance its first asset into clinical trials.